StockNews.AISignal intelligence
iRhythm Technologies, Inc. · NASDAQ · Healthcare
Browse public IRTC signals with their source context and measured market impact. Open any signal for its permanent analysis page.
iRhythm announced it will acquire Vital Connect, a private wearable biosensor maker. The deal could enhance iRhythm's sensing hardware, data analytics, and integrated patient monitoring platform, potentially accelerating time to monetization and expanding the addressable market in ambulatory monitoring. The terms and timeline were not disclosed, keeping near-term financial impact uncertain.
View signal analysisiRhythm expects 2025 revenue above $740 million with strong Q4 performance. 2026 revenue forecast of $870-$880 million shows 17-18% growth. Stock fell 20% due to Zio MCT launch delay to 2027. Analyst believes stock weakness is overblown; recommends buying. iRhythm maintains Outperform rating, expects solid long-term growth.
View signal analysisIRTC's Q3 loss of 6 cents beats expectations of a 31-cent loss. Sales reached $192.88 million, exceeding the $184.74 million consensus. Raised fiscal 2025 sales guidance to $735-$740 million, above $726.42 million consensus. Strong demand for Zio AT drives revenue and gross profit increase. Analysts maintain Buy ratings, with price forecasts raised significantly.
View signal analysisSpruce Point forecasts a 40%-70% long-term downside for IRTC stock. The report highlights regulatory and competitive challenges to IRTC's market position. Insiders sold $90 million to $160 million worth of stock amid safety concerns. iRhythm beat earnings expectations while raising sales guidance for 2025. AVALON study shows Zio service outperforms competitors in cardiac monitoring.
View signal analysisiRhythm reported Q1 2025 revenue of $158.7 million, exceeding estimates. Adjusted EPS loss narrowed to 95 cents, outperforming consensus estimates. Launch of Zio ECG system in Japan enhances international growth prospects. Wells Fargo and Baird raise price targets, indicating positive market sentiment. iRhythm projects 2025 sales guidance of $690-$700 million, above previous estimates.
View signal analysisFDA approved iRhythm's 510(k) submission for Zio AT device. Zio AT device remains available for shipping in the U.S. Management expects second approval soon, possibly by October. Analysts view updates positively, indicating progress in FDA alignment. Enhanced telemetry technology may improve competitive position.
View signal analysis